ID   OCUM-2M/SN38
AC   CVCL_IV71
DR   Wikidata; Q54931831
RX   PubMed=20393015;
RX   PubMed=21997136;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI_8988; SN-38 (7-ethyl-10-hydroxy-camptothecin).
CC   Derived from site: In situ; Stomach; UBERON=UBERON_0000945.
DI   NCIt; C9159; Gastric diffuse adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_8383 ! OCUM-2M
SX   Female
AG   49Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 19-12-24; Version: 8
//
RX   PubMed=20393015;
RA   Zhang X.-T., Yashiro M., Qiu H., Nishii T., Matsuzaki T., Hirakawa K.;
RT   "Establishment and characterization of multidrug-resistant gastric
RT   cancer cell lines.";
RL   Anticancer Res. 30:915-921(2010).
//
RX   PubMed=21997136; DOI=10.1038/bjc.2011.397; PMCID=PMC3242520;
RA   Yashiro M., Qiu H., Hasegawa T., Zhang X., Matsuzaki T., Hirakawa K.;
RT   "An EGFR inhibitor enhances the efficacy of SN38, an active metabolite
RT   of irinotecan, in SN38-refractory gastric carcinoma cells.";
RL   Br. J. Cancer 105:1522-1532(2011).
//